RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$6.22B
1-Year Return
46.93%
This Quarter Return
+14.68%
1 Year Return
+46.93%
3 Year Return
+140.96%
5 Year Return
+327.45%
10 Year Return
–
AUM
$3.38B
AUM Growth
+$703M
(+26%)
Cap. Flow
+$485M
Cap. Flow
% of AUM
14.34%
Top 10 Holdings %
Top 10 Hldgs %
44.12%
Holding
72
New
14
Increased
22
Reduced
16
Closed
3
Top Buys
| 1 |
Vistra
VST
|
$84.6M |
| 2 |
iShares Bitcoin Trust
IBIT
|
$69.7M |
| 3 |
QuidelOrtho
QDEL
|
$68.1M |
| 4 |
Fluor
FLR
|
$46.1M |
| 5 |
Extreme Networks
EXTR
|
$39.8M |
Top Sells
| 1 |
Collegium Pharmaceutical
COLL
|
$35.9M |
| 2 |
GoodRx Holdings
GDRX
|
$26.7M |
| 3 |
Koppers
KOP
|
$24M |
| 4 |
Mr. Cooper
COOP
|
$20.8M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$17.5M |
Sector Composition
| 1 | Healthcare | 47.6% |
| 2 | Technology | 8.46% |
| 3 | Financials | 7.86% |
| 4 | Industrials | 6.07% |
| 5 | Materials | 5.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xperi
XPER
$275M
| $48.8M | 1.44% |
4,043,744
+1,488,112
| +58% | +$17.9M |
|
|
MREO
27
Mereo BioPharma
MREO
$270M
| $44.7M | 1.32% |
13,552,997
| – | – |
|
28
AAR Corp
AIR
$2.75B
| $43.4M | 1.28% |
725,000
-170,904
| -19% | -$10.2M |
|
29
Kiniksa Pharmaceuticals
KNSA
$2.62B
| $43.3M | 1.28% |
2,196,009
-711,492
| -24% | -$14M |
|
|
PLYA
30
DELISTED
Playa Hotels & Resorts
PLYA
| $40.3M | 1.19% |
4,155,840
-275,321
| -6% | -$2.67M |
|
|
31
Extreme Networks
EXTR
$2.93B
| $39.8M | 1.18% |
+3,450,000
| New | +$39.8M |
|
32
Dave & Buster's
PLAY
$836M
| $37.5M | 1.11% |
+598,503
| New | +$37.5M |
|
33
Zymeworks
ZYME
$1.08B
| $36.6M | 1.08% |
3,475,384
| – | – |
|
34
Atmus Filtration Technologies
ATMU
$3.68B
| $36.5M | 1.08% |
+1,132,056
| New | +$36.5M |
|
35
Adaptive Biotechnologies
ADPT
$1.95B
| $33.7M | 1% |
10,500,000
+7,637,271
| +267% | +$24.5M |
|
36
Liberty Global Class C
LBTYK
$4.11B
| $33.4M | 0.99% |
1,893,293
+40,437
| +2% | +$713K |
|
|
37
Koppers
KOP
$557M
| $31.6M | 0.93% |
572,658
-434,683
| -43% | -$24M |
|
38
TransAlta
TAC
$3.55B
| $30.1M | 0.89% |
4,687,158
-458,472
| -9% | -$2.95M |
|
39
Par Pacific Holdings
PARR
$1.79B
| $28.6M | 0.85% |
772,384
-427,365
| -36% | -$15.8M |
|
40
Cannae Holdings
CNNE
$1.09B
| $27M | 0.8% |
1,214,217
+851,256
| +235% | +$18.9M |
|
41
Schrodinger
SDGR
$1.4B
| $27M | 0.8% |
+998,276
| New | +$27M |
|
42
Avis
CAR
$5.38B
| $26.3M | 0.78% |
+215,092
| New | +$26.3M |
|
43
Coherus Oncology, Inc. Common Stock
CHRS
$156M
| $24.9M | 0.73% |
10,400,000
+10,004,793
| +2,532% | +$23.9M |
|
44
Riskified
RSKD
$714M
| $22.6M | 0.67% |
4,173,636
| – | – |
|
|
SWTX
45
DELISTED
SpringWorks Therapeutics
SWTX
| $21M | 0.62% |
+426,768
| New | +$21M |
|
46
FTAI Infrastructure
FIP
$481M
| $20.1M | 0.59% |
3,193,530
| – | – |
|
47
Nuvalent
NUVL
$5.72B
| $19.7M | 0.58% |
+261,874
| New | +$19.7M |
|
48
Trevi Therapeutics
TRVI
$852M
| $19.2M | 0.57% |
5,564,123
-120,297
| -2% | -$415K |
|
49
scPharmaceuticals
SCPH
$298M
| $17.7M | 0.52% |
3,525,000
+25,000
| +0.7% | +$126K |
|
50
Ovid Therapeutics
OVID
$93.9M
| $16.2M | 0.48% |
5,315,969
| – | – |
|